Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Patent
1997-10-14
2000-11-21
Rose, Shep K.
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
424489, A61K 910, A61K 912, A61K 914
Patent
active
061498920
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
Drugs for treating respiratory and nasal disorders are frequently administered in aerosol formulations through the mouth or nose. One widely used method for dispensing such aerosol drug formulations involves making a suspension formulation of the drug as a finely divided powder in a liquefied gas known as a propellant. The suspension is stored in a sealed container capable of withstanding the pressure required to maintain the propellant as a liquid. The suspension is dispersed by activation of a dose metering valve affixed to the container.
A metering valve may be designed to consistently release a fixed, predetermined mass of the drug formulation upon each activation. As the suspension is forced from the container through the dose metering valve by the high vapor pressure of the propellant, the propellant rapidly vaporizes leaving a fast moving cloud of very fine particles of the drug formulation. This cloud of particles is directed into the nose or mouth of the patient by a channelling device such as a cylinder or open ended cone. Concurrently with the activation of the aerosol dose metering valve, the patient inhales the drug particles into the lungs or nasal cavity. Systems of dispensing drugs in this way are known as "metered dose inhalers" (MDI's). See Peter Byron, Respiratory Drug Delivery, CRC Press, Boca Raton, Fla. (1990) for a general background on this form of therapy.
Patients often rely on medication delivered by MDI's for rapid treatment of respiratory disorders which are debilitating and in some cases, even life threatening. Therefore, it is essential that the prescribed dose of aerosol medication delivered to the patient consistently meet the specifications claimed by the manufacturer and comply with the requirements of the FDA and other regulatory authorities. That is, every dose in the can must be the same within close tolerances.
Some aerosol drugs tend to adhere to the inner surfaces, i.e., walls of the can, valves, and caps, of the MDI. This can lead to the patient getting significantly less than the prescribed amount of drug upon each activation of the MDI. The problem is particularly acute with hydrofluoroalkane (also known as simply "fluorocarbon" propellant systems, e.g., P134a and P227, under development in recent years to replace chlorofluorocarbons such as P11, P114, and P12.
We have found that coating the interior can surfaces of MDI's with a fluorocarbon polymer significantly reduces or essentially eliminates the problem of drug adhesion or deposition on the can walls and thus ensures consistent delivery of medication in aerosol form from the MDI.
SUMMARY OF THE INVENTION
A metered dose inhaler having part or all of its internal metallic surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation comprising beclomethasone dipropionate or a physiologically acceptable solvate thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.
DETAILED DESCRIPTION OF THE INVENTION
The term "metered dose inhaler" or "MDI" means a unit comprising a can, a crimped cap covering the mouth of the can, and a drug metering valve situated in the cap, while the term "MDI system" also includes a suitable channelling device. The terms "MDI can" means the container without the cap and valve. The term "drug metering valve" or "MDI valve" refers to a valve and its associated mechanisms which delivers a predetermined amount of drug formulation from an MDI upon each activation. The channelling device may comprise, for example, an actuating device for the valve and a cylindrical or cone-like passage through which medicament may be delivered from the filled MDI can via the MDI valve to the nose or mouth of a patient, e.g. a mouthpiece actuator. The relation of the parts of a typical MDI is illustrated in U.S. Pat. No. 5,261,538 incorporated herein by reference.
U.S. Pat. No.
REFERENCES:
patent: 2562118 (1951-07-01), Osdal et al.
patent: 2721010 (1955-10-01), Meshberg
patent: 2886217 (1959-05-01), Thiel
patent: 2892576 (1959-06-01), Ward
patent: 2968427 (1961-01-01), Meshberg
patent: 2980301 (1961-04-01), De Gorter
patent: 3049269 (1962-08-01), Gawthrop
patent: 3052382 (1962-09-01), Gawthrop
patent: 3505737 (1970-04-01), Smith et al.
patent: 3611990 (1971-10-01), Paoletti et al.
patent: 3896602 (1975-07-01), Petterson
patent: 3929537 (1975-12-01), Erwin
patent: 3962171 (1976-06-01), Robbins
patent: 4087026 (1978-05-01), Petterson
patent: 4125152 (1978-11-01), Kestner et al.
patent: 4143204 (1979-03-01), Fang
patent: 4180609 (1979-12-01), Vassiliou
patent: 4335121 (1982-06-01), Phillipps et al.
patent: 4339483 (1982-07-01), Ueno et al.
patent: 4407481 (1983-10-01), Bolton et al.
patent: 4423823 (1984-01-01), Franek et al.
patent: 4487878 (1984-12-01), Vasta
patent: 4626157 (1986-12-01), Franek et al.
patent: 4741934 (1988-05-01), Terayama et al.
patent: 4819834 (1989-04-01), Thiel
patent: 4826132 (1989-05-01), Moldenhauer
patent: 4861647 (1989-08-01), Ishikawa et al.
patent: 4897439 (1990-01-01), Rau et al.
patent: 4902318 (1990-02-01), Stevens et al.
patent: 4945008 (1990-07-01), Heyes et al.
patent: 4961966 (1990-10-01), Stevens et al.
patent: 4969577 (1990-11-01), Werding
patent: 4972037 (1990-11-01), Garbe et al.
patent: 4980210 (1990-12-01), Heyes
patent: 4992474 (1991-02-01), Skidmore et al.
patent: 5006383 (1991-04-01), Achille et al.
patent: 5043191 (1991-08-01), Endres et al.
patent: 5061140 (1991-10-01), Hamaguchi et al.
patent: 5168107 (1992-12-01), Tannenbaum
patent: 5176132 (1993-01-01), Drought et al.
patent: 5192548 (1993-03-01), Velasquez et al.
patent: 5202110 (1993-04-01), Dalby et al.
patent: 5208226 (1993-05-01), Palmer
patent: 5221576 (1993-06-01), Bosc et al.
patent: 5225183 (1993-07-01), Purewal et al.
patent: 5250356 (1993-10-01), Batzar
patent: 5261538 (1993-11-01), Evans et al.
patent: 5270305 (1993-12-01), Palmer
patent: 5340463 (1994-08-01), Layre et al.
patent: 5345980 (1994-09-01), Burt et al.
patent: 5376359 (1994-12-01), Johnson
patent: 5411771 (1995-05-01), Tsai
patent: 5421492 (1995-06-01), Barger et al.
patent: 5447600 (1995-09-01), Webb
patent: 5468798 (1995-11-01), Leech
patent: 5503144 (1996-04-01), Bacon
patent: 5508023 (1996-04-01), Byron et al.
patent: 5536583 (1996-07-01), Roberts et al.
patent: 5597433 (1997-01-01), Dyble et al.
patent: 5605674 (1997-02-01), Purewal et al.
patent: 5674472 (1997-10-01), Akehurst et al.
patent: 5674473 (1997-10-01), Purewal et al.
patent: 5674592 (1997-10-01), Clark et al.
patent: 5676929 (1997-10-01), Akehurst et al.
patent: 5681545 (1997-10-01), Purewal et al.
patent: 5683676 (1997-11-01), Akehurst et al.
patent: 5683677 (1997-11-01), Purewal et al.
patent: 5695743 (1997-12-01), Purewal et al.
patent: 5720940 (1998-02-01), Purewal et al.
Budavari, The Merck Index, 11.sup.th th Ed., Merck & Co., Inc., pp. 37, 158-159 and 663-664 (1989).
Henry, The British Medical Assoc. Guide to Medicines & Drugs, Korling, Kindersley London, p. 137 (1992).
Kohler, Aerosols in Medicine, Chapter 12, pp. 303-319 (1993).
Buckton, International J. Pharm., vol. 83, pp. 163-170 (1992).
Journal of Teflon, vol. 4, No. 7, pp. 1, 4-6 (1963).
Journal of Teflon, vol. 1, No. 4, pp. 1 and 7 (1960).
Encyclopedia of Polymer Science and Engineering, vol. 16, pp. 557-642 (1971).
Kunststoff-Handbuch, Bank XI, Section 4.3.6.2, pp. 362-363 (1971).
Kirk-Othmer Encyclopedia of Chemical Technology, vol. 11, 3.sup.rd Ed., pp. 1-49 (1980).
Byron, Respiratory Drug Delivery, CRC Press, Inc., FL, pp. 167-201 (1990).
Lachman et al., Pharmaceutical Aerosols, Chapter 20, pp. 589-618 (1986).
Dalby et al., Pharmaceutical Technology, pp. 26-33, (1990).
Chemistry and Industry, p. 347 (1988).
Remington's Pharmaceutical Sciences, A. Gennaro, Ed., Mack Publishing Co., pp. 1670-1677 (1985).
Dadswell Charles E.
GlaxoWellcome, Inc.
Rose Shep K.
LandOfFree
Metered dose inhaler for beclomethasone dipropionate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metered dose inhaler for beclomethasone dipropionate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metered dose inhaler for beclomethasone dipropionate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1254199